MedVector - Telemedicine for Clinical Trials offering is now closed and is no longer accepting investments.

INVEST IN MEDVECTOR - TELEMEDICINE FOR CLINICAL TRIALS TODAY!

Transforming Clinical Trials

MedVector is an industry-first telemedicine platform that greatly accelerates clinical trials. By connecting subjects from anywhere in the world to existing clinical trial sites, MedVector has proven to exponentially increase clinical trial participation and dramatically accelerate FDA approval. Our service generates revenue for doctors and hospitals, reduces costs to clinical trial sponsors, and brings life-changing, advanced medicine to the market more quickly.

This Reg CF offering is made available through StartEngine Capital, LLC. This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment.
MedVector - Telemedicine for Clinical Trials

$906,237.52 Raised

REASONS TO INVEST

Reasons Icon

The Clinical Trials Market is currently worth ~$47 billion, with a predicted value of $104 billion based on our extensive research.

Reasons Icon

We have one of the world's largest clinical trial networks, obtaining access to 7 hospitals consisting of hundreds of thousands of patients per year.

Reasons Icon

During our case studies with Novartis, our progress greatly excelled against traditional patient recruitment services. In just 7 weeks we were able to do what often takes years.

ABOUT

HEADQUARTERS

898 N. Pacific Coast Highway
El Segundo , CA 90245
VALUATION

$10.02M

MedVector is an industry-first telemedicine platform that greatly accelerates clinical trials. By connecting subjects from anywhere in the world to existing clinical trial sites, MedVector has proven to exponentially increase clinical trial participation and dramatically accelerate FDA approval. Our service generates revenue for doctors and hospitals, reduces costs to clinical trial sponsors, and brings life-changing, advanced medicine to the market more quickly.

TEAM

Scott Stout
Scott Stout
CO-FOUNDER / CEO

Scott Stout is a Co-Founder and the CEO of MedVector. Prior to founding MedVector, Scott was an investment specialist at Morgan Stanley and an options strategist with D&S Investments. He has helped numerous startups with their investor models, valuations, and go-to-market strategies. His investor acumen, financial expertise and entrepreneurial spirt, make him an excellent leader for MedVector’s mission.

Dr. Dennis J. Patterson
Dr. Dennis J. Patterson
CO-FOUNDER / SVP MEDICAL AFFAIRS

Dr. Patterson is a senior hospital administrator turned entrepreneur (7 startups, 1 major exit, Wellspring Partners). He has been instrumental in devising and implementing healthcare programs that dramatically improve performance in some of the nation’s top hospitals and health systems. Dr. Patterson has held pivotal roles in senior management at Wellspring Partners, HealthcareNet, FHP Consulting, Ernst & Young, Westcare Consultants, Shaughnessy, Vancouver General, Misercordia, and Oak Forest Hospitals. He lectures internationally on healthcare issues and is the author of numerous books and publications including Indexing Managed Care (McGraw-Hill).

TERMS

MedVector - Telemedicine for Clinical Trials
Overview
PRICE PER SHARE
$1.45
DEADLINE
Jul 30, 2021
VALUATION
$10.02M
AMOUNT RAISED
$906,237.52
Breakdown
MIN INVESTMENT
$495.90
MAX INVESTMENT
$106,999.85
MIN NUMBER OF SHARES OFFERED
6,896
OFFERING TYPE
Equity
ASSET TYPE
COMMON
SHARES OFFERED
Common Stock
MAX NUMBER OF SHARES OFFERED
737,931

Maximum Number of Shares Offered subject to adjustment for bonus shares


Company

:

MedVector Corp

Corporate Address

:

898 N. Pacific Coast Highway, El Segundo , CA 90245

Offering Minimum

:

$9,999.20

Offering Maximum

:

$1,069,999.95

Minimum Investment Amount

(per investor)

:

$495.90











Terms


Offering Type

:

Equity

Security Name

:

Common Stock

Minimum Number of Shares Offered

:

6,896

Maximum Number of Shares Offered

:

737,931

Price per Share

:

$1.45

Pre-Money Valuation

:

$10,017,538.15











COVID Relief

This offering is being conducted on an expedited basis due to circumstances relating to COVID-19 and pursuant to the SEC’s temporary regulatory COVID-19 relief set out in Regulation Crowdfunding §227.201(z).

Expedited closing sooner than 21 days

In reliance on Regulation Crowdfunding §227.303(g)(2) A funding portal that is an intermediary in a transaction involving the offer or sale of securities initiated between May 4, 2020, and August 31, 2020, in reliance on section 4(a)(6) of the Securities Act (15 U.S.C. 77d(a)(6)) by an issuer that is conducting an offering on an expedited basis due to circumstances relating to COVID-19 shall not be required to comply with the requirement in paragraph (e)(3)(i) of this section that a funding portal not direct a transmission of funds earlier than 21 days after the date on which the intermediary makes publicly available on its platform the information required to be provided by the issuer under §§227.201 and 227.203(a).

Company Perks*

Early Bird

Friends and Family - First 72 hours | 20% bonus shares

Super Early Bird - Next 72 hours | 15% bonus

Early Bird Bonus - Next 7 days | 10% bonus shares

Volume

Tier 1 perk - ($10,000 + 5% bonus shares)

Tier 2 perk - ($25,000+ 10% bonus shares)

Tier 3 perk - ($50,000+ 15% bonus shares)

*All perks occur when the offering is completed.

Voting Proxy. Each Subscriber shall appoint the Chief Executive Officer of the Company (the “CEO”), or his or her successor, as the Subscriber’s true and lawful proxy and attorney, with the power to act alone and with full power of substitution, to, consistent with this instrument and on behalf of the Subscriber, (i) vote all Securities, (ii) give and receive notices and communications, (iii) execute any instrument or document that the CEO determines is necessary or appropriate in the exercise of its authority under this instrument, and (iv) take all actions necessary or appropriate in the judgment of the CEO for the accomplishment of the foregoing. The proxy and power granted by the Subscriber pursuant to this Section are coupled with an interest. Such proxy and power will be irrevocable. The proxy and power, so long as the Subscriber is an individual, will survive the death, incompetency and disability of the Subscriber and, so long as the Subscriber is an entity, will survive the merger or reorganization of the Subscriber or any other entity holding the Securities. However, the Proxy will terminate upon the closing of a firm-commitment underwritten public offering pursuant to an effective registration statement under the Securities Act of 1933 covering the offer and sale of Common Stock or the effectiveness of a registration statement under the Securities Exchange Act of 1934 covering the Common Stock.

Irregular Use of Proceeds

The Company might incur Irregular Use of Proceeds that may include but are not limited to the following over $10,000: Vendor payments. Salary payments made to one’s self, a friend or relative. Any expense labeled “Travel and Entertainment”.

PRESS

Article Image
Karten Design

IMPROVING CLINICAL TRIAL SPEED THROUGH TELEMEDICINE

Article Image
Voyage LA

Meet Scott Stout of MedVector Clinical Trials

ALL UPDATES

07.22.21

Industry Traction & New Explainer Video

Currently MedVector has signed NDAs with 9 Pharma/CROs and are analyzing 22 protocols.  Things are getting exciting over here! Our new explainer video has been very helpful!  

https://youtu.be/91Co05LcVpg

07.13.21

The industry is talking about MedVector!


07.12.21

Check out our new explainer video!

Our new explainer video is designed to help industry experts understand how MedVector unlocks access to patients behind non-research physicians who don't refer to clinical trials.  We also have another video coming out shortly outlining how data is entered using MedVector (Hint: It's captured the same way as without MedVector.)

MedVector Unlocks Access to Patients (New)

06.23.21

MedVector CEO named "20 Most Influential Healthcare Entrepreneurs to Watch in 2021"

DRIVEN TO EXPAND CLINICAL TRIALS BEYOND TRIAL SITES


Scott Stout is driven by the desire to compete ─ either racing downhill mountain bikes, riding motorcycles, or growing a business. If there’s someone quicker, smarter or more experienced, so much the better for the agile and entrepreneurial Stout, who loves to compete and win, but doesn’t always have to be “the best.” In fact, he says, “When I’m the best, I just feel like the competition isn’t strong enough.  When I’m in the pack, I push harder.”


READ THE FULL ARTICLE HERE


Scott Stout, Founder and CEO, MedVector Clinical Trials

06.16.21

Notice of Funds Disbursement

[The following is an automated notice from the StartEngine team].

Hello!

As you might know, MedVector - Telemedicine for Clinical Trials has exceeded its minimum funding goal. When a company reaches its minimum on StartEngine, it's about to begin withdrawing funds. If you invested in MedVector - Telemedicine for Clinical Trials be on the lookout for an email that describes more about the disbursement process.


This campaign will continue to accept investments until its indicated closing date.


Thanks for funding the future.

-StartEngine

04.28.21

Notice of Material Change in Offering

[The following is an automated notice from the StartEngine team].

Hello! Recently, a change was made to the MedVector - Telemedicine for Clinical Trials offering. Here's an excerpt describing the specifics of the change:


MedVector has extended their campaign and added 2020 financials.


When live offerings undergo changes like these on StartEngine, the SEC requires that certain investments be reconfirmed. If your investment requires reconfirmation, you will be contacted by StartEngine via email with further instructions.

04.19.21

Notice of Material Change in Offering

[The following is an automated notice from the StartEngine team].

Hello! Recently, a change was made to the MedVector - Telemedicine for Clinical Trials offering. Here's an excerpt describing the specifics of the change:


MedVector Corp is extending their campaign.


When live offerings undergo changes like these on StartEngine, the SEC requires that certain investments be reconfirmed. If your investment requires reconfirmation, you will be contacted by StartEngine via email with further instructions.

03.15.21

Notice of Funds Disbursement

[The following is an automated notice from the StartEngine team].

Hello!

As you might know, MedVector - Telemedicine for Clinical Trials has exceeded its minimum funding goal. When a company reaches its minimum on StartEngine, it's about to begin withdrawing funds. If you invested in MedVector - Telemedicine for Clinical Trials be on the lookout for an email that describes more about the disbursement process.


This campaign will continue to accept investments until its indicated closing date.


Thanks for funding the future.

-StartEngine

01.19.21

Notice of Funds Disbursement

[The following is an automated notice from the StartEngine team].

Hello!

As you might know, MedVector - Telemedicine for Clinical Trials has exceeded its minimum funding goal. When a company reaches its minimum on StartEngine, it's about to begin withdrawing funds. If you invested in MedVector - Telemedicine for Clinical Trials be on the lookout for an email that describes more about the disbursement process.


This campaign will continue to accept investments until its indicated closing date.


Thanks for funding the future.

-StartEngine

11.11.20

Notice of Funds Disbursement

[The following is an automated notice from the StartEngine team].

Hello!

As you might know, MedVector - Telemedicine for Clinical Trials has exceeded its minimum funding goal. When a company reaches its minimum on StartEngine, it's about to begin withdrawing funds. If you invested in MedVector - Telemedicine for Clinical Trials be on the lookout for an email that describes more about the disbursement process.


This campaign will continue to accept investments until its indicated closing date.


Thanks for funding the future.

-StartEngine

REWARDS

Multiple investments in an offering cannot be combined to qualify for a larger campaign perk. Get rewarded for investing more into MedVector - Telemedicine for Clinical Trials.

$10,000.00

Tier 1 perk

($10,000 + 5% bonus shares)

$25,000.00

Tier 2 perk

($25,000+ 10% bonus shares)

$50,000.00

Tier 3 perk

($50,000+ 15% bonus shares)

JOIN THE DISCUSSION













0/2500

HOW INVESTING WORKS

Cancel anytime before 48 hours before a rolling close or the offering end date.

WHY STARTENGINE?

REWARDS

We want you to succeed and get the most out of your money by offering rewards and memberships!

SECURE

Your info is your info. We take pride in keeping it that way!

DIVERSE INVESTMENTS

Invest in over 200 start-ups and collectibles!

With Regulation A+, a non-accredited investor can only invest a maximum of 10% of their annual income or 10% of their net worth per year, whichever is greater. There are no restrictions for accredited investors.

With Regulation Crowdfunding, non-accredited investors with an annual income or net worth less than $124,000, are limited to invest a maximum of 5% of the greater of those two amounts. For those with an annual income and net worth greater than $124,000, he/she is limited to investing 10% of the greater of the two amounts.

At the close of an offering, all investors whose funds have “cleared” by this time will be included in the disbursement. At this time, each investor will receive an email from StartEngine with their Countersigned Subscription Agreement, which will serve as their proof of purchase moving forward.

Please keep in mind that a company can conduct a series of “closes” or withdrawals of funds throughout the duration of the campaign. If you are included in that withdrawal period, you will be emailed your countersigned subscription agreement and proof of purchase immediately following that withdrawal.

StartEngine assists companies in raising capital, and once the offering is closed, we are no longer involved with whether the company chooses to list shares on a secondary market, or what occurs thereafter. Therefore, StartEngine has no control or insight into your investment after the close of the live offering. In addition, we are not permitted to provide financial advice. You may want to contact a financial professional to discuss possible investment outcomes.

For Regulation Crowdfunding, investors are able to cancel their investment at any point throughout the campaign up until 48 hours before the closing of the offering. Note: If the company does a rolling close, they will post an update to their current investors, giving them the opportunity to cancel during this timeframe. If you do not cancel within this 5-day timeframe, your funds will be invested in the company, and you will no longer be able to cancel the investment. If your funds show as ‘Invested’ on your account dashboard, your investment can no longer be canceled.

For Regulation A+, StartEngine allows for a four-hour cancelation period. Once the four-hour window has passed, it is up to each company to set their own cancelation policy. You may find the company’s cancelation policy in the company’s offering circular.

Once your investment is canceled, there is a 10-day clearing period (from the date your investment was submitted). After your funds have cleared the bank, you will receive your refund within 10 business days.

Refunds that are made through ACH payments can take up to 10 business days to clear. Unfortunately, we are at the mercy of the bank, but we will do everything we can to get you your refund as soon as possible. However, every investment needs to go through the clearing process in order to get sent back to the account associated with the investment.

Both Title III (Regulation Crowdfunding) and Title IV (Reg A+) help entrepreneurs crowdfund capital investments from unaccredited and accredited investors. The differences between these regulations are related to the investor limitations, the differing amounts of money companies are permitted to raise, and differing disclosure and filing requirements. To learn more about Regulation Crowdfunding, click here, and for Regulation A+, click here.

RAISED
$906,237.52
INVESTORS
555
MIN INVEST
$495.90
VALUATION
$10.02M

@ 2022 All Rights Reserved

Apple Store Logo

Get To Know Us

Our Team

Careers

Blog

Important Message

IN MAKING AN INVESTMENT DECISION, INVESTORS MUST RELY ON THEIR OWN EXAMINATION OF THE ISSUER AND THE TERMS OF THE OFFERING, INCLUDING THE MERITS AND RISKS INVOLVED. INVESTMENTS ON STARTENGINE ARE SPECULATIVE, ILLIQUID, AND INVOLVE A HIGH DEGREE OF RISK, INCLUDING THE POSSIBLE LOSS OF YOUR ENTIRE INVESTMENT.


www.StartEngine.com is a website owned and operated by StartEngine Crowdfunding, Inc. (“StartEngine”), which is neither a registered broker-dealer, investment advisor nor funding portal.


Unless indicated otherwise with respect to a particular issuer, all securities-related activity is conducted by regulated affiliates of StartEngine: StartEngine Capital, LLC, a funding portal registered here with the US Securities and Exchange Commission (SEC) and here as a member of the Financial Industry Regulatory Authority (FINRA), or StartEngine Primary, LLC, a broker-dealer registered with the SEC and FINRA/SIPC . You can review the background of our broker-dealer and our investment professionals on FINRA’s BrokerCheck here. StartEngine Secondary is an alternative trading system regulated by the SEC and operated by StartEngine Primary, LLC, a broker dealer registered with the SEC and FINRA. StartEngine Primary, LLC is a member of SIPC and explanatory brochures are available upon request by contacting SIPC at (202) 371-8300.


Investment opportunities posted and accessible through the site are of three types:


1) Regulation A offerings (JOBS Act Title IV; known as Regulation A+), which are offered to non-accredited and accredited investors alike. These offerings are made through StartEngine Primary, LLC (unless otherwise indicated). 2) Regulation D offerings (Rule 506(c)), which are offered only to accredited investors. These offerings are made through StartEngine Primary, LLC. 3) Regulation Crowdfunding offerings (JOBS Act Title III), which are offered to non-accredited and accredited investors alike. These offerings are made through StartEngine Capital, LLC. Some of these offerings are open to the general public, however there are important differences and risks.


Any securities offered on this website have not been recommended or approved by any federal or state securities commission or regulatory authority. StartEngine and its affiliates do not provide any investment advice or recommendation and do not provide any legal or tax advice with respect to any securities. All securities listed on this site are being offered by, and all information included on this site is the responsibility of, the applicable issuer of such securities. StartEngine does not verify the adequacy, accuracy or completeness of any information. Neither StartEngine nor any of its officers, directors, agents and employees makes any warranty, express or implied, of any kind whatsoever related to the adequacy, accuracy, or completeness of any information on this site or the use of information on this site. See additional general disclosures here.


By accessing this site and any pages on this site, you agree to be bound by our Terms of use and Privacy Policy, as may be amended from time to time without notice or liability.


Canadian Investors Investment opportunities posted and accessible through the site will not be offered to Canadian resident investors. Potential investors are strongly advised to consult their legal, tax and financial advisors before investing. The securities offered on this site are not offered in jurisdictions where public solicitation for offerings is not permitted; it is solely your responsibility to comply with the laws and regulations of your country of residence.


California Investors Only – Do Not Sell My Personal Information (800-317-2200). StartEngine does not sell personal information. For all customer inquiries, please write to contact@startengine.com.


StartEngine’s Reg A+ offering is made available through StartEngine Crowdfunding, Inc. This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment. For more information about this offering, please view StartEngine’s offering circular and risk associated with this offering.